Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of FerGene.

    Client Virtual Booth

    FERGENE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    FerGene
    Switzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    FERRING INTERNATIONAL CENTER S.A., CH. DE LA VERGOGNAUSAZ 50, 1162 SAINT-PREX
    Telephone
    Telephone
    41 58 301 00 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ferring.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/x4-pharmaceuticals
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    FerGene Reports Landmark Study in Non-Muscle Invasive Bladder Cancer Testing Breakthrough Investigational Gene Therapy Nadofaragene Firadenovec Publishe...

    Details:

    Novel rAd-IFN/Syn3 intravesical gene therapy given once every three months studied in patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer.


    Lead Product(s): Nadofaragene firadenovec

    Therapeutic Area: Oncology Product Name: rAd-IFN/Syn3

    Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 30, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    FerGene to Present Bladder Cancer Data at 2020 ASCO

    Details:

    Data highlight a need for bladder-sparing therapies to improve outcomes for patients with high-grade, non-muscle invasive bladder cancer.


    Lead Product(s): Nadofaragene firadenovec

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 10, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search